Rekombinanter VWF Antikörper (AA 1815-1939)

Produktnummer ABIN5646933

Dieses Kaninchen Monoklonal-Antikörper erkennt spezifisch VWF in WB, IP, IF und IHC (p). Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für Rekombinanter VWF Antikörper (AA 1815-1939) (ABIN5646933)

Target: VWF (Von Willebrand Factor (VWF))

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Dieser VWF Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunoprecipitation (IP), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Klon: VWF-1859R

Produktdetails anti-VWF Antikörper

Bindungsspezifität: AA 1815-1939

Aufreinigung: Purified

Reinheit: Protein A affinity chromatography

Immunogen: Amino acids 1815-1939 from the human protein were used as the immunogen for this recombinant vWF antibody.

Isotyp: IgG kappa

Anwendungsinformationen

Applikationshinweise: The optimal dilution of the recombinant vWF antibody for each application should be determined by the researcher.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Western blot: 1-2 μg/mL,Immunoprecipitation: 1-2 μg/500 μg lysate,Immunofluorescence: 1-2 μg/mL,Immunohistochemistry (FFPE): 1-2 μg/mL for 30 minutes at RT

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store the recombinant vWF antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Details zu VWF

Target: VWF (Von Willebrand Factor (VWF))

Andere Bezeichnung: von Willebrand Factor / vWF

Hintergrund: Von Willebrand Factor (vWF) is a multimeric glycoprotein that is found in endothelial cells, plasma and platelets. It acts as a carrier protein for Factor VIII and promotes platelet adhesion and aggregation. vWF undergoes a variety of posttranslational modifications that influence the affinity and availability for Factor VIII, including cleavage of the propeptide and formation of N-terminal disulfide bonds. This antibody helps to establish the endothelial nature of some lesions of disputed histogenesis, e.g. Kaposi's sarcoma and cardiac myxoma. It is widely used for differentiating vascular lesions from those of other tissue differentiation within a panel of other vascular markers although not all tumors of endothelial differentiation contain this antigen.